Literature DB >> 31679615

Early Evidence for the Role of lncRNA TUG1 in Vascular Remodelling in Pulmonary Hypertension.

Sébastien Bonnet1, Olivier Boucherat2, Steeve Provencher2, Roxane Paulin2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31679615     DOI： 10.1016/j.cjca.2019.06.023

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN： 0828-282X            Impact factor:   5.223


× No keyword cloud information.
  5 in total

1.  LncRNA HOXA-AS3 Promotes the Progression of Pulmonary Arterial Hypertension through Mediation of miR-675-3p/PDE5A Axis.

Authors:  Zhong-Kui Li; Lu-Fang Gao; Xi-An Zhu; Dao-Kang Xiang
Journal:  Biochem Genet       Date:  2021-03-09       Impact factor: 1.890

2.  The Long-Noncoding RNA TUG1 Regulates Oxygen-Induced Retinal Neovascularization in Mice via MiR-299.

Authors:  Yue Wang; Xue Wang; Yue-Xia Wang; Yuan Ma; Yu Di
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-01-03       Impact factor: 4.799

Review 3.  MiRNAs, lncRNAs, and circular RNAs as mediators in hypertension-related vascular smooth muscle cell dysfunction.

Authors:  Ji-Ru Zhang; Hai-Jian Sun
Journal:  Hypertens Res       Date:  2020-09-23       Impact factor: 3.872

4.  LncRNA PAXIP1-AS1 fosters the pathogenesis of pulmonary arterial hypertension via ETS1/WIPF1/RhoA axis.

Authors:  Rong Song; Si Lei; Song Yang; Shang-Jie Wu
Journal:  J Cell Mol Med       Date:  2021-07-10       Impact factor: 5.310

5.  Construction and analysis of the abnormal lncRNA-miRNA-mRNA network in hypoxic pulmonary hypertension.

Authors:  Jie Liu; Yishu Deng; Zeqin Fan; Shuanglan Xu; Li Wei; Xiaoxian Huang; Xiqian Xing; Jiao Yang
Journal:  Biosci Rep       Date:  2021-08-27       Impact factor: 3.840
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.